CRO PharPoint Research Expands Consulting Services
Due to high demand CRO PharPoint Research has expanded its facilities to providing consulting services. The consulting division will handle scientific development strategies for the firm’s clients.
CRO PharPoint Research is a contract research based organisation based in North Carolina, USA. In line with a growing trend within the pharmaceutical industry, Pharpoint has recently sought to move beyond contract research, investing heavily in the consulting sector, as the group seeks to diversify its client base and grow profits. Pharpoint, which the Research Triangle Park deemed one of the fastest growing companies in the world, provides clients with clinical development services to pharmaceutical and biotech companies, keeping their goals in mind which emphasises top quality customer service and special attention to detail in order to provide clients with the best service possible.
The company is expanding its advisory services into the pharmaceutical consulting industry at a time when numerous pharmaceutical companies are also looking to cash in on the potentially lucrative sector. Conglomerate UDG Healthcare recently also sealed a $22 million deal to purchase American management consulting firm Vynamic. Smaller consultancies have been increasingly seen as a benefit to the global healthcare sector as a whole, as greater emphasis continues to be placed on improving healthcare efficiencies and innovation. The complexity of the healthcare market has paved the way for expertise offered by smaller and therefore more flexible consulting firms to become increasingly attractive for health companies.
This latest expansion by Pharpoint will likely make it an attractive prospect in line with that trend, as founding Partner and Chief Scientific Officer Dr. Jennifer A. Elder, leads the project in-house. The new consulting division will seek to deliver scientific and strategic development approaches to clients working with the fields of study design, clinical trial logistics, and regulatory representation. Dr. Elder will be accompanied by Senior Director of Consulting Operations Dr. Amy Flynt, Director of Consulting Operations Moya Hawkins, alongside a group of therapeutic development experts.
Dr. Elder explained the future of the consulting divison when she stated,"By formalising our consulting division, we are uniquely positioned to provide expertise to small pharmaceutical and biotechnology companies that do not have internal capabilities in biostatistics, data management, or clinical operations." Since it’s establishment in 2007, PharPoint has gained prominence in the CRO industry, as a response to the client’s needs PharPoint has dedicated an entire division to consulting.
“We have been successful at keeping the consultative approach as part of our core business philosophy,” said Art Holmes, Research’s CEO.
